Cardiff Oncology and Nerviano settle litigation, amend onvansertib license

Cardiff Oncology, Inc.

Settlement resolves Cardiff v. Nerviano (Case No. 3:26-cv-03131-RBM-JLB) with mutual releases; no money exchanged
Amended license adds exclusivity framework, additional license fee on annual net sales, and development milestones
Nerviano gets board observer plus Scientific Advisory Board seat; revised post-termination royalty tiers added
Revised assignment provision: Cardiff owes NMS percentage of proceeds if change of control before Phase III data readout
Amendment effective upon dismissal with prejudice; existing license otherwise remains in force

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.